Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction

NCT04327024 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04327024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04327024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2020
Completion date
April 29, 2022
Enrollment
159 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction (hfpef)